Tags

Type your tag names separated by a space and hit enter

Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
J Med Econ. 2016 Jul; 19(7):684-95.JM

Abstract

Objective Peginterferon beta-1a 125 mcg, administered subcutaneously (SC) every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved by the US Food and Drug Administration in 2014. This study assesses the cost-effectiveness of peginterferon beta-1a vs interferon beta-1a (44 mcg SC 3 times per week) and glatiramer acetate (20 mg SC once-daily) in the treatment of RRMS from the perspective of a US payer over 10 years. Methods A Markov cohort economic model was developed for this analysis. The model predicts disability progression, occurrence of relapses and other adverse events and translates them into quality-adjusted life years (QALYs) and costs. Natural history data were obtained from the placebo arm of the ADVANCE trial of peginterferon beta-1a, the London Ontario (Canada) database and a large population-based MS survey. Comparative efficacy of each DMT vs placebo was obtained from a network meta-analysis. Costs (in 2014 US dollars) were sourced from public databases and literature. Clinical and economic outcomes were discounted at 3% per year. Results Over 10 years, peginterferon beta-1a was dominant (i.e., more effective and less costly), with cost-savings of $22,070 and additional 0.06 QALYs when compared with interferon beta-1a 44 mcg and with cost-savings of $19,163 and 0.07 QALYs gained when compared with glatiramer acetate 20 mg. Results were most sensitive to variations in the treatment effect of each DMT, treatment acquisition costs of each DMT and the time horizon. Probabilistic sensitivity analyses indicated that peginterferon beta-1a remains dominant in >90% of 5,000 replications compared with either DMTs. Conclusion This analysis suggests that long-term treatment with peginterferon beta-1a improves clinical outcomes at reduced costs compared with interferon beta-1a 44 mcg and glatiramer acetate 20 mg and should be a valuable addition to managed care formularies for treating patients with RRMS.

Authors+Show Affiliations

a Evidera , 430 Bedford St. Suite 300 , Lexington , MA 02420 , USA ;a Evidera , 430 Bedford St. Suite 300 , Lexington , MA 02420 , USA ;b Biogen , Landis & Gyr-Strasse 3 , 6300 Zug , Switzerland ;c Biogen , 133 Boston Post Road , Weston , MA 02493 , USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

26947984

Citation

Hernandez, Luis, et al. "Cost-effectiveness Analysis of Peginterferon Beta-1a Compared With Interferon Beta-1a and Glatiramer Acetate in the Treatment of Relapsing-remitting Multiple Sclerosis in the United States." Journal of Medical Economics, vol. 19, no. 7, 2016, pp. 684-95.
Hernandez L, Guo S, Kinter E, et al. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. J Med Econ. 2016;19(7):684-95.
Hernandez, L., Guo, S., Kinter, E., & Fay, M. (2016). Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. Journal of Medical Economics, 19(7), 684-95. https://doi.org/10.3111/13696998.2016.1157080
Hernandez L, et al. Cost-effectiveness Analysis of Peginterferon Beta-1a Compared With Interferon Beta-1a and Glatiramer Acetate in the Treatment of Relapsing-remitting Multiple Sclerosis in the United States. J Med Econ. 2016;19(7):684-95. PubMed PMID: 26947984.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States. AU - Hernandez,Luis, AU - Guo,Shien, AU - Kinter,Elizabeth, AU - Fay,Monica, Y1 - 2016/03/07/ PY - 2016/3/8/entrez PY - 2016/3/8/pubmed PY - 2017/6/9/medline KW - Peginterferon beta-1a – Cost-effectiveness – Multiple sclerosis – United States SP - 684 EP - 95 JF - Journal of medical economics JO - J Med Econ VL - 19 IS - 7 N2 - Objective Peginterferon beta-1a 125 mcg, administered subcutaneously (SC) every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved by the US Food and Drug Administration in 2014. This study assesses the cost-effectiveness of peginterferon beta-1a vs interferon beta-1a (44 mcg SC 3 times per week) and glatiramer acetate (20 mg SC once-daily) in the treatment of RRMS from the perspective of a US payer over 10 years. Methods A Markov cohort economic model was developed for this analysis. The model predicts disability progression, occurrence of relapses and other adverse events and translates them into quality-adjusted life years (QALYs) and costs. Natural history data were obtained from the placebo arm of the ADVANCE trial of peginterferon beta-1a, the London Ontario (Canada) database and a large population-based MS survey. Comparative efficacy of each DMT vs placebo was obtained from a network meta-analysis. Costs (in 2014 US dollars) were sourced from public databases and literature. Clinical and economic outcomes were discounted at 3% per year. Results Over 10 years, peginterferon beta-1a was dominant (i.e., more effective and less costly), with cost-savings of $22,070 and additional 0.06 QALYs when compared with interferon beta-1a 44 mcg and with cost-savings of $19,163 and 0.07 QALYs gained when compared with glatiramer acetate 20 mg. Results were most sensitive to variations in the treatment effect of each DMT, treatment acquisition costs of each DMT and the time horizon. Probabilistic sensitivity analyses indicated that peginterferon beta-1a remains dominant in >90% of 5,000 replications compared with either DMTs. Conclusion This analysis suggests that long-term treatment with peginterferon beta-1a improves clinical outcomes at reduced costs compared with interferon beta-1a 44 mcg and glatiramer acetate 20 mg and should be a valuable addition to managed care formularies for treating patients with RRMS. SN - 1941-837X UR - https://www.unboundmedicine.com/medline/citation/26947984/Cost_effectiveness_analysis_of_peginterferon_beta_1a_compared_with_interferon_beta_1a_and_glatiramer_acetate_in_the_treatment_of_relapsing_remitting_multiple_sclerosis_in_the_United_States_ DB - PRIME DP - Unbound Medicine ER -